Kowa, JW Pharmaceutical and Merck side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Kowa | JW Pharmaceutical | Merck |
|---|---|---|---|
| Phase 1 | 00% | JW Pharmaceutical: 12 of its 17 programs at phase 1
and 7 more — sign in to see them all | Merck: 27 of its 84 programs at phase 1 and 22 more — sign in to see them all |
| Phase 2 | 00% | 00% | Merck: 19 of its 84 programs at phase 2
and 14 more — sign in to see them all |
| Phase 3 | 00% | JW Pharmaceutical: 3 of its 17 programs at phase 3
| Merck: 35 of its 84 programs at phase 3
and 30 more — sign in to see them all |
| Approved, new studies | Kowa: 1 of its 1 programs at approved, new studies
| JW Pharmaceutical: 2 of its 17 programs at approved, new studies
| Merck: 3 of its 84 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kowa1 readouts · 1 phase 3 | · | · | · | · | · | · | · | · | Kowa, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · |
| JW Pharmaceutical2 readouts · 1 phase 3 | · | JW Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion
| · | · | JW Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | · | · | · | · |
| Merck25 readouts · 6 phase 3 | Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Merck, Dec ’26: 3 programs whose next study reaches primary completion
| Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3
| Merck, Feb ’27: 4 programs whose next study reaches primary completion
| Merck, Mar ’27: 1 program whose next study reaches primary completion
| Merck, Apr ’27: 3 programs whose next study reaches primary completion
| Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Merck, Jun ’27: 2 programs whose next study reaches primary completion
| Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Merck, Aug ’27: 1 program whose next study reaches primary completion
| Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Merck, Oct ’27: 2 programs whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Kowa
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
JW Pharmaceutical
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Merck
New programs 7
- V951Aphase 1 · first study · Nov 10
- pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
- MK-2750phase 2 · first study · Oct 9 · Neoplasms
- MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
- V175phase 1 · first study · Sep 28
- V175Aphase 1 · first study · Sep 28
Merck: new programs in 90 days
- V951Aphase 1 · first study · Nov 10
- pyronaridinephase 1 · first study · Oct 30
- MK-2750phase 2 · first study · Oct 9
- MK-6255phase 1 · first study · Oct 6
- V175phase 1 · first study · Sep 28
and 2 more — sign in to see them all
Reached a new phase 2
Study stopped 4
- pembrolizumabphase 2 · terminated Nov 18“Business Reasons” · NCT04428151
- pembrolizumabphase 3 · terminated Sep 28“The study stopped due to futility” · NCT03833167
- pembrolizumabphase 3 · terminated Sep 28“The study stopped due to futility” · NCT03834493
- pembrolizumabphase 3 · terminated Sep 28“The study stopped due to futility” · NCT04191096
Primary completion later 6
- opevesostatphase 3 · Aug 2028 → Nov 2028 (+4 mo) · moved Nov 5 · NCT06136624
- pembrolizumabphase 3 · Jul 2026 → Jul 2028 (+24 mo) · moved Oct 23 · NCT03711032
- patritumab deruxtecanphase 2 · Apr 2030 → Aug 2032 (+27 mo) · moved Oct 21 · NCT06686394
- ifinatamab deruxtecanphase 2 · Apr 2031 → Oct 2031 (+6 mo) · moved Oct 9 · NCT06863272
- Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Oct 2028 → Mar 2031 (+28 mo) · moved Oct 6 · NCT06818643
- pembrolizumabphase 2 · Nov 2026 → Feb 2027 (+3 mo) · moved Oct 2 · NCT03407144
Where they overlap
Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.
| Condition | Kowa | JW Pharmaceutical | Merck |
|---|---|---|---|
| Hypercholesterolemiaall three · compare here | Kowa in Hypercholesterolemia: 1 program
Their studies: Kowa’s studies of Hypercholesterolemia in search | JW Pharmaceutical in Hypercholesterolemia: 1 program
Their studies: JW Pharmaceutical’s studies of Hypercholesterolemia in search | Merck in Hypercholesterolemia: 3 programs
Their studies: Merck’s studies of Hypercholesterolemia in search |
| Dyslipidemiasall three · compare here | Kowa in Dyslipidemias: 1 program
Their studies: Kowa’s studies of Dyslipidemias in search | JW Pharmaceutical in Dyslipidemias: 2 programs
Their studies: JW Pharmaceutical’s studies of Dyslipidemias in search | Merck in Dyslipidemias: 1 program
Their studies: Merck’s studies of Dyslipidemias in search |
| Hyperlipidemiasall three · compare here | Kowa in Hyperlipidemias: 1 program
Their studies: Kowa’s studies of Hyperlipidemias in search | JW Pharmaceutical in Hyperlipidemias: 1 program
Their studies: JW Pharmaceutical’s studies of Hyperlipidemias in search | Merck in Hyperlipidemias: 2 programs
Their studies: Merck’s studies of Hyperlipidemias in search |
| Diabetes Mellitus, Type 22 of 3 · compare here | – | JW Pharmaceutical in Diabetes Mellitus, Type 2: 1 program
Their studies: JW Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search | Merck in Diabetes Mellitus, Type 2: 4 programs
Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search |
| Hypertension2 of 3 · compare here | – | JW Pharmaceutical in Hypertension: 1 program
Their studies: JW Pharmaceutical’s studies of Hypertension in search | Merck in Hypertension: 1 program
Their studies: Merck’s studies of Hypertension in search |
| Non-alcoholic Fatty Liver Disease2 of 3 · compare here | Kowa in Non-alcoholic Fatty Liver Disease: 1 program
Their studies: Kowa’s studies of Non-alcoholic Fatty Liver Disease in search | – | Merck in Non-alcoholic Fatty Liver Disease: 1 program
Their studies: Merck’s studies of Non-alcoholic Fatty Liver Disease in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.